Skip to main content
Premium Trial:

Request an Annual Quote

Evogene Raises Nearly $74M in US IPO

NEW YORK (GenomeWeb News) – Plant genomics firm Evogene has gone public in the US through the offering of 5 million shares of common stock at an offering price of $14.75 per share, bringing in gross proceeds of $73.75 million.

The firm has granted the underwriters a 30-day option to purchase up to 750,000 additional ordinary shares at the same offering price per share.

The Israel-based company, which also trades on the Tel Aviv Stock Exchange, filed to go public in the US in September, saying at the time that it intended to offer $60 million of its shares.

Evogene said that agricultural products giant Monsanto has agreed to purchase 813,560 ordinary shares as part of the offering for approximately US$12 million.

Evogene's shares are expected to begin trading today on the New York Stock Exchange under the symbol "EVGN."

Credit Suisse Securities and Deutsche Bank Securities acted as joint book-running managers on the planned offering, while Oppenheimer and Piper Jaffray were co-managers.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.